

06-20-00

A

**NON-PROVISIONAL
UTILITY PATENT APPLICATION
TRANSMITTAL - 37 CFR 1.53(b)**

☐ **Duplicate**
(check, if applicable)

Assistant Commissioner for Patents
BOX PATENT APPLICATION
Washington, DC 20231

Attorney Docket No. 4070-174US (K400417US)
First Named Inventor: Horst Peschel
Express Mail Label No. EL474257472US
Total Pages of Transmittal Form: 2

Transmitted herewith for filing is the non-provisional utility patent application entitled:

**Brain Tissue Derived from Neuronal Precursor Cells, it's use as Transplant and a Method
of Preparation thereof**

Which is:

an ☒ Original; or

a ☐ Continuation, ☐ Divisional, or ☐ Continuation-in-part (CIP)
of prior Application No. /, filed .

☐ This non-provisional patent application is based on Provisional Patent Application
No. , filed .

Enclosed are:

- ☒ Specification (including Abstract) and claims: 21 pages.
- ☒ Newly unexecuted Declaration (original).
- ☐ Copy of Declaration from prior application.
- ☐ Separate Power of Attorney (including 37 CFR 3.73(b) statement, if applicable).
- ☒ 1 sheets of drawings (formal) plus one copy.
- ☐ Microfiche computer program (Appendix).
- ☐ Nucleotide and/or Amino Acid Sequence Submission, including:
 - ☐ Computer readable copy ☐ Paper Copy ☐ Verified Statement.
- ☐ Under PTO-1595 cover sheet, an assignment of the invention.
- ☐ Certified copy of Application No., filed , is filed:
 - ☐ herewith or ☐ in prior application .
- ☐ Verified Statement Claiming Small Entity Status under 37 CFR 1.9 and 1.27.
 - ☐ was filed in the prior non-provisional application, and such status is still proper and desired (37 CFR 1.28(a));
 - ☐ is enclosed herewith; ☐ is no longer desired.
- ☐ Preliminary Amendment.
- ☐ Information Disclosure Statement, PTO-1449, and cited references.
- ☐ Other:

The filing fee has been calculated as shown below:

			SMALL ENTITY			LARGE ENTITY	
CLAIMS	NO. FILED	NO. EXTRA	BASIC FEE: \$345			BASIC FEE: \$690	
Total	25-20 =	5	X9	\$	OR	X18	\$
Independent	3- 3=	0	X39	\$	OR	X78	\$
Multiple Dependent Claims Present:			\$130	\$	OR	\$260	\$
			TOTAL	\$	OR	TOTAL	\$

The Commissioner is hereby authorized to charge payment of the following fees or credit any overpayment to Deposit Account No. 50-1017. One additional copy of this sheet is enclosed.

- ☐ The above calculated filing fee 0 - (Billing No. 204070.0174).
- ☐ Any additional fees required under 37 C.F.R. § 1.16.
- ☒ Any additional fees required under 37 C.F.R. §1.17.
- ☒ If the filing of any paper during the prosecution of this application requires an extension of time in order for the paper to be timely filed, applicant(s) hereby petition(s) for the appropriate extension of time pursuant to 37 C.F.R. §1.136(a).

CORRESPONDENCE ADDRESS:

June 19, 2000
(Date)

By:

for

Gary D. Colby

Registration No. 40,961

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

One Commerce Square

2005 Market Street - Suite 2200

Philadelphia, PA 19103

Telephone: 215-965-1200

Facsimile: 215-965-1210

E-Mail: gcolby@akingump.com

Direct Dial: 215-965-1285

☒ Customer Number or Bar Code Label: **000570**

GDC:jf

Enclosures

TITLE OF THE INVENTION

Brain Tissue Derived From Neuronal Precursor Cells, It's Use As Transplant And
A Method Of Preparation Thereof

BACKGROUND OF THE INVENTION

This invention relates to brain tissue, which is developed from immature neuronal precursor cells as a source for tissue transplantation in neurological and neurosurgical disorders and the method of generating such tissue.

Restorative treatment strategies have been have been exploited in respect to many neurological and neurosurgical disorders. The underlying idea is to replace dead or non-functional tissue by appropriate cell suspensions. There is a chance to treat, e. g. Parkinson's disease with Implants consisting of dopaminergic neurons, Alzheimer's disease with cholinergic neurons, Huntington's disease with striatal GABAergic neurons and multiple system atrophy with dopaminergic and GABAergic neurons.

Unfortunately, these treatment options are limited by the lack of appropriate tissue, which is derived from human embryos.

In addition, there is debate about the need for immunosuppressive therapy following transplantation. Most current protocols involve immunosuppression causing significant side effects.

Tissue derived from human embryos also needs to be transplanted into patients within a few days severely limiting microbiological and genetical testing.

SUMMARY OF THE INVENTION

The invention is based on the problem to develop a source of brain tissue, which can be used for transplantation therapy or from which such transplants can easily be derived. This tissue must not bear any of the above mentioned disadvantages. In addition, this invention includes the problem to present a method for manufacturing such tissue.

This invention is based on the concept that neuronal progenitor (precursor) cells can be isolated and expanded in vitro. The proliferation of said neuronal progenitor cells can be modulated using appropriate substances, e. g. proteins, in a way that these cells become determined to differentiate completely or predominantly into a specific cell type (e. g. dopaminergic neuron) after transplantation or, in general, after making contact with an appropriate substrate such as other cells or a supporting material. Using this treatment, one can generate tissue cultures that almost substantially contain immediate precursors of specific neurons. These cultures do not include cells that give rise to immunogenic glial cells in large enough quantities to induce any detectable immune response. Thus, the inventor can generate appropriate well-characterized tissue for transplantation with virtually unlimited supply.

Neuronal progenitor cells from which the issue for transplantation is derived can be isolated from embryonic or adult brain or spinal cord preparations. If an adult donor is used, neuronal progenitor cells are preferably isolated from subventricular or hippocampal brain regions.

Most efficiently, neuronal progenitor cells are prepared from human embryonic brain tissue, 3- 25 weeks of gestation, preferably 5 – 11 weeks of gestation.

Neuronal progenitor cells were successfully isolated from various parts of the brain. In addition, neuronal progenitor cells could also be isolated from human embryonic brain tissue (Buc-Caron, Neurobiol Dis 1995; 2:37-47; Svandsen CN et al., Exp Neurol 1997; 148:135-146; Sah et al., Nat Biotechnol 1997; 15:574-580; Chalmers-Redman et al., Neuroscience 1997; 76:1121-1128. The technique of preparation of brain tissue and isolation of neuronal progenitor cells has been adapted from these protocols.

15 The resulting tissue cultures differentiate into specific cell types preferably without
addition application of compounds or genetic engineering.

Partial differentiation and selection may be performed repeatedly with possible variation among individual treatments.

Expansion of neuronal progenitor cells may include a variation of atmospheric oxygen content, priming, transient or non-transient expression of foreign genes, treatment with exogenous compounds especially under reduced oxygen partial pressure, or a combination of these. These individual treatments will be explained in detail below.

The selection of determined progenitor cells includes generation of clonal cell lines, which may include a variation, especially a reduction, of atmospheric oxygen.

5

15

20

25

30

The exogenous mitogens (detailed description below) maybe used in concentrations varying from 4000 to 0.01 ng/ml, better 500 to 1 /ml, preferably 100 to 2 ng/ml. Concentrations outside these ranges are not excluded.

Partial differentiation using priming:

Priming includes intermittent treatment of (monoclonal) neuronal progenitor cells with one or more compounds that promote differentiation in specific neurons. These compounds include e. g. growth factors, cytokines, neurotransmitters. In addition, conditioned media may be employed. These media may be derived from primary cultures containing striatal, glial or other brain cells or used to cultivate these neurons. The media contain aminoacid compounds being secreted from these cells. Preferably cells of the target region of the neurons of choice are used. To generate tissue for transplantation these media may be serum-free. These compounds are removed after a period (preferably a few hours) that allows dedifferentiation into progenitor cells that maintain their capability to perform mitosis. Said primed progenitor cells respond to a subsequent treatment with such factors more rapidly. Said primed progenitor cells may be subcloned and/or expanded. Priming may be repeated several times using identical or alternative combinations and/or concentrations of differentiation promoting compounds.

Priming may be performed with a variety of substances (exogenous factors). One may use combinations of cytokines and growth factors, cytokines and neurotransmitters, cytokines and hormones, cytokines and gangliosides, cytokines and conditioned media, growth factors and neurotransmitters, growth factors and hormones, growth factors and gangliosides, growth factors and conditioned media, neurotransmitters and hormones, neurotransmitters and gangliosides, neurotransmitters and conditioned media, etc.

Any of the above mentioned combinations may again be combined.

25 Growth factors comprise one or more of the epidermal growth factor (EGF) family, preferably EGF1, EGF2, or EGF3 including α and β subgroups, transforming growth factor (TGF) α and β , LIN-3, fibroblast growth factor (FGF) 1 and 2, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophines (NT) 3,4,5 and 6, insulin like growth factor (IGF) 1 and 2, glial cell line-derived

30 neurotrophic factor (GDNF), Neurturin (NTN), Persephin (PSP), vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) including all members of individual families and proteins with similar mode of action.

Cytokines may include one or a combination of leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), the family of interleukines (IL1-16), tumor necrosis factor (TNF), especially $\text{TNF}\alpha$, interferones (IFN), especially IFN- α , macrophage inhibitory or stimulating factor, especially macrophage migration inhibitory factor (MIF), mitochondrial import stimulation factor (MSF) and retinoic acid.

Treatment with neurotransmitters may include one or a combination of dopamine, acetylcholine, GABA, glutamate, glycine, taurin, proline, noradrenaline, serotonin and various neuropeptides such as substance P and enkephaline.

In addition one or combinations of various hormones, especially steroid hormones or thyroid hormone, gangliosides, and their derivatives may be used.

Priming of neuronal progenitor cells in order to determine these to differentiate into dopaminergic neurons preferably includes treatment with GDNF, LIF, IL1, IL11 and/or thyroid hormone.

These exogenous compounds may be administered in concentrations ranging from 25,000 bis 0.005 ng/ml, better 1000 bis 0.1 ng/ml, preferably 100 bis 1 ng/ml expansion media. Concentrations outside these ranges are not excluded.

Especially, IL-1 concentrations of 0.005 to 10 ng/ml, preferably 0.01 to 2 ng/ml, especially between 0.05 to 0.25 ng/ml could be used. IL-11 and LIF could be applied in concentrations of 0.01 to 100 ng/ml, preferably 0.1 to 20 ng/ml, most preferably between 0.5 to 2.5 ng/ml. GDNF could be applied in concentrations from 1 to 25,000 ng/ml, preferably 1-10 to 5,000 ng/ml, most preferably between 1-100 to 2,500 ng/ml.

These concentrations of exogenous factors may also be used when combinations of any of these are employed. However, the actual concentrations are not limited to the above mentioned ranges and may vary depending on the combination.

Partial differentiation using transfection:

The generation of highly determined neuronal progenitor cells may also include genetic engineering, especially in combination with priming. Using transfection with genes that are known to be crucial for the development of specific

Determination to differentiate into dopaminergic neurons may be promoted via expression of members of the steroid or thyroid hormone receptors, tyrosine hydroxylase, NURR1 and/or NURR77. In addition, genes encoding for the vesicular monoamine transporter (VMAT2) or the dopamine transporter may be used. In general, all genes that play a role in the development of such neurons may be employed.

Progenitors determined to differentiate into GABAergic neurons may be generated via transient transfection with dopamine receptor, glutamate receptor, γ amino butyric acid transporters enkephaline and/or substance P genes.

Generation of monoclonal cell lines:

Subcloning may be performed using dilutions of single cell suspensions or may be aided using fluorescence-activated cell sorting (FACS) after labeling of vital cells or via enriching these cell suspensions using a magnetic column after labeling the cells with superparamagnetic beads or micromanipulation.

Subcloning with suspensions of single cells may be performed using gravity extraction of non-dissociated cells and dilution of the remaining single cells to a concentration calculated to contain only one cell per volume that is needed for

plating. Cells are plated in expansion media allowing for proliferation of monoclonal cell lines. Said monoclonal cell lines will be treated and characterized as described above.

5 Micromanipulation may be performed to increase the yield of monoclonal determined cell lines. Viable cells will be labeled with a fluorescent marker that is specific for the respective cell population. Using fluorescent microscopy single fluorescent cells can be identified and selected with appropriate tools such as a glass capillary. These cells may then give rise to monoclonal cell lines which have a much higher potential to be determined to differentiate into the cell

10 type of choice. Preferably mitogenic substances (see above) are added to the expansion media. Differentiation and characterization is conducted as described below. Neuronal progenitor cells that express the tyrosine hydroxylase gene may be labeled using expression of a fluorescent protein (e. g. EGFP) which is controlled by the promoter of the tyrosine hydroxylase or dopamine transporter gene. Similar

15 approaches may be used to identify neuronal progenitor cells that readily express specific proteins using the choline-acetyl-transferase promoter (cholinergic marker), glutamyl transferase (GABAergic marker) or other respective promoter elements. In addition, viable cells may also be identified using fluorescent antibodies to specific membrane localized proteins (dopamine transporter, nicotinic acetylcholine

20 receptors, especially α , β subunits (especially $\alpha 7$ subunits) GABA transporter, etc.).

Similar labeling techniques may also be employed to isolate specific neuronal progenitor cells using FACS. Said labeled cells may be separated from unlabeled cells using standard FACS protocols (for review: Orfao und Ruiz-

25 Arguelles, Clin Biochem 1996;29:5-9). These isolated cells may be expanded using polyclonal cell lines or via subcloning of monoclonal cell lines after dilution of single cell suspensions.

Magnetic isolation of determined neuronal progenitor cells may be performed using labeling of viable cells with superparamagnetic beads. These beads

30 are commercially available (Basic microbeads - dextran coated with free amines, 50nm, Miltenyi Biotech; Amino/Carboxy beads, 110-140 nm, Immunicon Corp.; Streptavidin/Biotin coated, Miltenyi Biotech or Immunicon Corp.).

Ligands for specific proteins (e. g. dopamine D2 receptor, dopamine transporter, nicotinic acetylcholine receptors, GABA transporter, serotonin

transporter, etc.) may be fused to the surface of these beads. Suspensions of individual cells may be incubated with these loaded beads. After binding of the magnetic beads to individual cells, these cells can be isolated via contact with a magnetic column. When the magnet in the column is turned off, cells that express the desired proteins can be eluted and used to generate polyclonal or monoclonal cell lines. Neuronal progenitor cells that express dopaminergic neuron specific proteins such as dopamine receptors or dopamine transporter may be identified using spiperone- or benzamide derivatives as ligands for dopamine D2 receptors or cocaine derivatives as ligand for the dopamine transporter. For labeling of GABAergic cells, ligands for the GABA transporter may be used. Cholinergic cells may be recognized using ligands for acetylcholine receptors.

All of the above mentioned procedures are used to isolate (subclone) cells which are highly determined to differentiate into a given cell type but maintain their ability to divide. These procedures include priming with exogenous factors that stimulate differentiation, expression of foreign genes and/or changes in atmospheric oxygen and nitrogen concentrations.

Expansion after subcloning, micromanipulation, magnetic isolation and/or FACS is always performed using identical or similar expansion media as described above.

All of the above mentioned procedures may be combined or repeated.

Isolation and expansion of neuronal progenitor cells:

1. Fetal and Adult Progenitor Cell Cultures (Expansion):
- Embryonic brain tissue from 5 to 12 weeks after gestation may be acquired under compliance with German Ärztekammer guidelines, germane government guidelines, and the local ethics committee and appropriate consent forms were used. Samples may be collected and the forebrain and ventral mesencephalon including the subependymal region may be dissected. To confirm the origin of midbrain samples, a small amount of tissue should be processed further for primary culture and stained for tyrosine hydroxylase (TH). The tissue samples may be serially incubated with serine protease such as trypsin (50 – 500 mg/ml) for 30 min at 23°C and DNase (20 - 60 µg/ml) for 2 - 30 min at 37°C, mechanically triturated to a quasi-single cell suspension and plated into un-coated 25 cm²-flasks (0.05 – 10

$\times 10^6$ cells per flask) in 5 ml expansion media, supplemented with efficient concentrations of mitogens (EGF, 10 - 100 ng/ml and/or FGF2, 5 to 100 ng/ml or others). Cultures may be placed in a humidified incubator at 37°C and 5% CO₂, 95 % air or at lowered O₂ conditions using a O₂-sensitive electrode system. Growth factors will be supplemented every other to every second day and cultures will be passed every 10 to 20 days. Cells may be labeled with BrdU with 10 μ M BrdU (Sigma) 2,4 and 7 days after plating for 24 h. The expansion media may contain mitogens and 10 – 60 % F12 or 30 – 60 % Dulbecco's Modified Eagle's Medium (DMEM; without glucose or with various glucose concentrations), efficient concentrations of an antibiotic (50 to 250 units/ml penicilline and 50 to 250 μ g/ml streptomycine). IN addition, the expansion media may contain one or combinations of the following compounds: transferring, diamines, especially putrescine,, sodiumselenit, gestagens, especially progesterone or similar compounds and insulin. Commercially available mixtures of supplements such as B27 (Gibco) may be used instead or in addition.

2. Expansion in altered atmospheric conditions: Normal room air contains about 20 % oxygen and less than 1 % CO₂. Tissue culturing is usually performed in air that contains the same amount of oxygen (20 %) and 1-10, preferably about 5 % CO₂. The rate of proliferation of various neuronal progenitor cells depends on this air composition. As indicated above human midbrain derived progenitor cells and cells that differentiate into dopaminergic neurons are specifically promoted using reduced oxygen condition. Neuronal progenitor cells may, therefore, be incubated in adequate systems that allow tight and continuous control not only of CO₂ but also oxygen content and indirectly nitrogen content using a O₂-sensitive electrode system. Oxygen concentrations may vary between less than 1 % and 30 %. To promote proliferation of progenitor cells determined to differentiate into dopaminergic neurons 1% - 5 % oxygen are preferably employed.

3. Transfection of Cells with Genes: One may transfect cells during proliferation to prepare these cells for cell sorting. Plasmid DNA may be added in concentrations of 0.1 – 5 μ g / ml, preferably 0.5 – 1.0 μ g of plasmid DNA per ml content of tissue culture flask and appropriate amounts of commercially available transfection reagents, e. g. 3 μ l per μ g DNA of TransFast (Promega) solution (prepared according to the instructions of the manufacturer). This solution may be incubated at 37°C and then added to the tissue culture flasks. To identify

5

10

15

25

30

4. **Toxicological Assays:** *MTT assay:* After incubation of the cultures with the substance of interest, 30 μ l of MTT reagent (0.5 mg/ml MTT in PBS containing 10 mM HEPES) may be added to each well and incubated in at 37°C for 2 h. The medium is aspirated from each well and the culture plate dried at 37°C for 1 h. The resulting formazan dye can be extracted with 100 μ l acid-isopropanol and the absorbency measured spectrophotometrically using computer-operated immuno reader at a wavelength of 570 nm with reference at 630 nm. Wells without cells will be used as blanks and are subtracted as background from each sample. *Trypan blue exclusion method:* The trypan blue assay will be carried out according to standard procedures.

5. Immunocytochemistry: Cultures may be fixed using 3.7% paraformaldehyde and washed with PBS. After blocking with normal serum, primary antibody may be added and incubated over night at 4°C. The following day, primary antibody may be removed and biotinylated secondary antibody added for 1 h followed by visualization via the ABC system coupled to nickel/DAB/H₂O₂ reaction or fluorescence-conjugated antibody. All cultures may be incubated with secondary antibody without primary antibody to ensure the specificity of the reaction. All plates may be assessed for the distinct staining by an individual blinded to treatment history. For visualization of dopamine cells anti-tyrosine hydroxylase and anti-dopamine transporter antibodies may be used, for GABAergic cells antibodies against anti-GAD65 & 67, for cholinergic cells antibodies against ChAT, for glial cells anti-GFAP antibodies, for neurons anti-MAP2 and anti- β -tubulin III, for oligodendrocytes anti-O4 antibodies may be used. For anti-BrdU staining to demonstrate proliferation of the cells the method according to the manufacturer (RPN-20 kit; Amersham) may be used. For double staining (in particular anti-BrdU and TH, anti-tubuline and TH or GAD) to demonstrate specific neuronal and glial phenotypes from progenitor cell origin, immunofluorescence stained cultures may be assessed using the fluorescence microscope equipped with visual analysis system (Axiovert 135; Zeiss).

6. Transmitter High-Affinity Uptake Studies: Functional integrity of DA and GABA neurons may be evaluated by measuring the uptake of their respective tritiated neurotransmitter. After preincubation for 10 min in incubation buffer containing 100 μ M pargyline, 1 mM ascorbate, and 2 mM β -alanine (and for determination of nonspecific uptake: 3 μ M GBR12909 and 1 mM 2,4-diamino-*n*-butyric acid; DABA), 50 nM [³H]DA. [³H]choline or [³H]GABA may be added for 15 min at 37°C. Uptake may be stopped by washing the dishes with cold PBS and the remaining radioactivity in the cell lysate may be measured using liquid scintillation counting. Specific uptake may be defined as the difference between the uptake measured in the absence (total) and the uptake measured in the presence of GBR12909 and DABA (nonspecific).

7. Determination of Dopamine, Acetylcholine and GABA by HPLC: For determination of dopamine, GABA and acetylcholine a HPLC-based method may be used. Determination of acetylcholine and GABA may be performed using standard procedures.

CLAIMS

I claim:

1. Isolated brain derived tissue not containing any physiologically active amounts of immunocompetent glial cells.
2. Said tissue described in claim 1, almost substantially consisting of dopaminergic neurons, cholinergic neurons, GABAergic neurons, and/or serotonergic neurons or differentiate into these neurons.
3. Said tissue described in claim 1, substantially consisting of dopaminergic neurons or cells that can differentiate into dopaminergic neurons.
4. Said tissue described in claim 1, substantially consisting of cholinergic neurons or cells that can differentiate into cholinergic neurons.
5. Said tissue described in claim 1, substantially consisting of GABAergic striatal neurons or cells that can differentiate into GABAergic striatal neurons.
6. Said tissue described in claim 1, substantially consisting of serotonergic neurons or cells that can differentiate into serotonergic neurons.
7. Said tissue described in claim 1, further characterized that the tissue is derived from mammals, especially humans.
8. Said tissue described in claim 7, further characterized that this is derived from developing immature (progenitor) cells.
9. Tissue that is useful to restore neuronal deficits after transplantation generated according to claim 1.
10. Monoclonal cell line derived from mammalian, especially human, progenitor cells characterized by exclusive or predominant differentiation into neurons when exposed to differentiation promoting factors.

11. Method to generate an expandable tissue culture derived from progenitor cells comprising the following individual steps:
 - dissection of mammalian brain tissue
 - isolation of progenitor cells
 - proliferation of progenitor cells
 - partial differentiation of progenitor cells
 - if necessary repetition of at least one of the steps isolation, proliferation and partial differentiation
12. Method according to claim 11, further characterized by selecting individual cells using subcloning
13. Said method described in claim 12, using one or multiple of the following procedures in suitable sequences:
 - subcloning using final dilution
 - subcloning using micromanipulation
 - subcloning using fluorescence activated cell sorting
 - subcloning using labeling and isolation with super-paramagnetic beads.
14. Said method described in claim 11, further characterized by the fact that the selection and partial differentiation of progenitor cells may be performed in conditions with reduced or increased oxygen/ nitrogen content or conditions that simulate reduced or increased oxygen/nitrogen content.
15. Said method described in claim 12, further characterized by the fact that oxygen content is less than 10 %, preferably less than 5 %.
16. Said method described in claim 12, further characterized by the fact that the conditions induced by reduced oxygen content may be simulated by application of compounds such as inhibitors of mitochondrial energy production.

17. Said method described in claim 11, further characterized by the fact that the progenitor cells are partially differentiated using expression of foreign genes or priming.

18. Said method described in claim 11, further characterized by the fact that the progenitor cells are partially differentiated by priming using treatment with appropriate cytokines, growth factors, hormones, neurotransmitters, transcription factors and/or gangliosides for periods of time that induce expression of tissue specific genes but do not preclude proliferation.

19. Said method described in claim 18, further characterized by the fact that priming is induced by one or a combination of members of the following growth factor families: EGF, FGF, GDNF, TGF α and β , LIN-3-protein, NGF, BDNF, NT, PDNF, IGF and/or VEGF, including respective subunits.

20. Said method described in claim 18, further characterized by the fact that priming is induced by one or a combination of the following cytokines: LIF, CNTF, interleukines (IL1-16), interferones, MIF, MSF, retinoic acid.

21. Said method described in claim 18, further characterized by the fact that priming is induced by one or a combination of the following neurotransmitters: dopamine, acetylcholine, GABA, glutamate, glycine, taurine, proline, noradrenaline, serotonin, substance P, enkephaline.

22. Said method described in claim 18, further characterized by the fact that priming is induced in monoclonal progenitor cell lines.

23. Said method described in claim 11, further characterized by the fact that proliferation of progenitor cells is achieved under hypoxic conditions or addition of exogenous factors.

24. Tissue culture generated according to claim 18.


[illegible]

5

This invention relates to neuronal tissue which is suitable to restore neuronal deficits following transplantation. To reduce immunological side effects and to increase the microbiological and genetic safety of the tissue we propose tissue that does not contain glial cells and is maintained in vitro for prolonged periods. The method to generate expandable determined neuronal progenitor cell cultures includes the following procedures: dissection of appropriate mammalian brain regions, isolation of progenitor cells, expansion of progenitor cells, selection and expansion of individual cells and priming.

	0.0	0.1	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1.0	1.1	1.2	1.3	1.4	1.5	1.6	1.7	1.8	1.9	2.0	2.1	2.2	2.3	2.4	2.5	2.6	2.7	2.8	2.9	3.0	3.1	3.2	3.3	3.4	3.5	3.6	3.7	3.8	3.9	4.0	4.1	4.2	4.3	4.4	4.5	4.6	4.7	4.8	4.9	5.0	5.1	5.2	5.3	5.4	5.5	5.6	5.7	5.8	5.9	6.0	6.1	6.2	6.3	6.4	6.5	6.6	6.7	6.8	6.9	7.0	7.1	7.2	7.3	7.4	7.5	7.6	7.7	7.8	7.9	8.0	8.1	8.2	8.3	8.4	8.5	8.6	8.7	8.8	8.9	9.0	9.1	9.2	9.3	9.4	9.5	9.6	9.7	9.8	9.9	10.0
0.0	0.0000	0.0001	0.0002	0.0003	0.0004	0.0005	0.0006	0.0007	0.0008	0.0009	0.0010	0.0011	0.0012	0.0013	0.0014	0.0015	0.0016	0.0017	0.0018	0.0019	0.0020	0.0021	0.0022	0.0023	0.0024	0.0025	0.0026	0.0027	0.0028	0.0029	0.0030	0.0031	0.0032	0.0033	0.0034	0.0035	0.0036	0.0037	0.0038	0.0039	0.0040	0.0041	0.0042	0.0043	0.0044	0.0045	0.0046	0.0047	0.0048	0.0049	0.0050	0.0051	0.0052	0.0053	0.0054	0.0055	0.0056	0.0057	0.0058	0.0059	0.0060	0.0061	0.0062	0.0063	0.0064	0.0065	0.0066	0.0067	0.0068	0.0069	0.0070	0.0071	0.0072	0.0073	0.0074	0.0075	0.0076	0.0077	0.0078	0.0079	0.0080	0.0081	0.0082	0.0083	0.0084	0.0085	0.0086	0.0087	0.0088	0.0089	0.0090	0.0091	0.0092	0.0093	0.0094	0.0095	0.0096	0.0097	0.0098	0.0099	0.0100

5



DECLARATION AND POWER OF ATTORNEY
(Original Application)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
Brain Tissue Derived from Neuronal Precursor Cells, it's use as Transplant and a Method of Preparation thereof

the specification of which is attached hereto and/or was filed on June 19, 2000 application No. _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to herein.

I acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d), of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

FOREIGN PRIORITY APPLICATION(S)

<u>199 28 210.2</u>	<u>Germany</u>	<u>19 June 1999</u>
(Number)	(Country)	(Day/month/year filed)

Priority Claimed
☒ Yes ☐ No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional patent application(s) listed below and have also identified below any

United States provisional patent application(s) having a filing date before that of the application on which priority is claimed:

PROVISIONAL PRIORITY PATENT APPLICATION(S)

Priority Claimed

☐ Yes ☐ No

(Application No.)

(Filing Date)

And I hereby appoint the registered attorneys and agents associated with **AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., Customer No. 000570**, as my attorneys or agents with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Address all correspondence to **Customer No. 000570, namely, AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.**, One Commerce Square, 2005 Market Street, Suite 2200, Philadelphia, Pennsylvania 19103. Please direct all communications and telephone calls to Gary D. Colby at 215-965-1285.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole

inventor, if any Horst Peschel

Inventor's Signature _____

Date _____

Residence Gummersbach, Germany


Citizenship German

Post Office Address Mühlenstr. 14c, 51643 Gummersbach

Germany

00696507-064900

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

there are only 18 pages of specification

☐ Scanned copy is best available.